Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

– Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody – Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year – Ipsen expands rare disease portfolio to include serious and frequent post-transplant infection with no targeted approved treatments PARIS, FRANCE […] The post Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio first appeared on Memo Therapeutics .